- Profit after tax (consolidated)
- Rs 395.8 mn
- EPS
- Rs 7.40 +24.4%
- EPS a year earlier
- Rs 5.95
PSX Pharmaceuticals
FEROZ Ferozsons Laboratories Limited
Latest results: FY2026 · Jun 2026
FY2026 revenue Rs 24.0 bn (+27.0%), profit Rs 978.6 mn (+26.0%). Dividend paid 3 years in a row.
Last close · 13 Nov 2026
Rs 362.49 ▼ 5.47 (-1.49%)
▼ 8.7% 1 year
- Market cap
- Rs 15.8 bn
- P/E
- 16.1×
- FY2026
- Sector 12.6× · higher
- P/B
- 1.19×
- FY2026
- Sector 3.11× · lower
- Dividend yield
- 1.5%
- FY2026
- Payers 4.7% · lower
- ROE
- 7.6%
- FY2026
- Sector 21.7% · lower
- EPS
- Rs 22.51
- FY2026
- Book value / share
- Rs 304.56
- FY2026
Fundamentals
FEROZ at a glance
Revenue · FY2026
Rs 24.0 bn
▲ 27.0% year on year
Profit attributable to shareholders · FY2026
Rs 978.6 mn
▲ 26.0% year on year
EPS – basic (Rs) · FY2026
Rs 22.51
▲ 26.0% year on year
Dividend per share (Rs) · FY2026
Rs 5.50
▲ 37.5% year on year
Net margin · FY2026
5.1%
+0.2 pts year on year
Debt to equity · FY2026
27.3%
-2.4 pts year on year
Price performance
FEROZ returns
Close Rs 362.49
13 Nov 2026
| Period | Return | Rs | vs KSE-100 |
|---|---|---|---|
| MTD Month to date | +3.9% −3.0 pts vs KSE | +13.46 | −3.0 pts KSE +6.9% |
| 3M 3 months | −3.3% −2.0 pts vs KSE | −12.20 | −2.0 pts KSE −1.2% |
| 6M 6 months | −3.9% −10.1 pts vs KSE | −14.67 | −10.1 pts KSE +6.2% |
| YTD Year to date | −3.5% −5.7 pts vs KSE | −13.25 | −5.7 pts KSE +2.2% |
| FYTD Fiscal year to date | −10.1% −8.8 pts vs KSE | −40.69 | −8.8 pts KSE −1.4% |
| 1Y 1 year | −8.7% −19.4 pts vs KSE | −34.50 | −19.4 pts KSE +10.7% |
| Long term | |||
| 3Y 3 years | +82.1% +22.1% a year −132.6 pts vs KSE | +163.38 | −132.6 pts KSE +214.7% |
| 5Y 5 years | +15.8% +3.0% a year −273.0 pts vs KSE | +49.58 | −273.0 pts KSE +288.8% |
Price return from the last close before each period; the fiscal year ends 30 June. Dividends are not included.
Ferozsons Laboratories Limited in brief
Ferozsons Laboratories Limited (FEROZ) reported revenue of Rs 24.0 bn for FY2026 (Jul 2025 – Jun 2026), up 27.0% from FY2025.
Profit attributable to shareholders was Rs 978.6 mn (EPS Rs 22.51), up 26.0%, a net margin of 5.1%.
It declared a dividend of Rs 5.50 per share for FY2026 and has paid a dividend in each of the last 3 years.
Net debt stood at Rs 3.2 bn.
Return on equity was 7.6%.
Over the last five years revenue grew at a compound 22.0% a year.
At Rs 362.49 (close on 13 Nov 2026) the shares trade at 16.1× earnings (FY2026) and 1.19× book value, with a dividend yield of 1.5%.
Scorecard vs Pharmaceuticals
14 companies- Growth
- Strong
- 27.9%
- Profitability
- Below average
- 5.1%
- Financial health
- Below average
- 27.3%
- Valuation
- Below average
- 16.1×
- Dividends
- Average
- 1.5%
Ratings place the company in its sector: growth (3-year revenue growth), profitability (net margin; return on equity for banks, insurers and finance companies), financial health (debt to equity, industrial companies), valuation (P/E at today's price) and dividends (yield at today's price). Five dots = top fifth. Rated within the sector when at least four companies report the figure, otherwise against all PSX companies of the same type (marked vs PSX). Information, not investment advice.
Corporate
FEROZ announcements & payouts
- Profit after tax (unconsolidated)
- Rs 219.6 mn
- EPS
- Rs 5.05 -15.1%
- EPS a year earlier
- Rs 5.95
- Profit after tax (consolidated)
- Rs 1,227.7 mn
- EPS
- Rs 22.51 +26.0%
- EPS a year earlier
- Rs 17.86
- Profit after tax (unconsolidated)
- Rs 650.9 mn
- EPS
- Rs 14.97 -16.2%
- EPS a year earlier
- Rs 17.86
Book closure 21 Oct – 28 Oct 2026 · Buy by Fri 16 Oct (est.) for the payout
Financial highlights
FEROZ financial results
| Rs bn | FY2026 Jul 2025 – Jun 2026 | FY2025 Jul 2024 – Jun 2025 | FY2024 Jul 2023 – Jun 2024 | FY2023 Jul 2022 – Jun 2023 | FY2022 Jul 2021 – Jun 2022 | FY2021 Jul 2020 – Jun 2021 | FY2020 Jul 2019 – Jun 2020 | FY2019 Jul 2018 – Jun 2019 | FY2018 Jul 2017 – Jun 2018 | FY2017 Jul 2016 – Jun 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 24.0 | 18.9 | 15.9 | 11.5 | 9.3 | 8.9 | 6.2 | 5.8 | 5.1 | 5.0 |
| Gross profit | 10.7 | 8.0 | 6.5 | 4.3 | 4.0 | 3.7 | 2.3 | 2.0 | 1.6 | 1.9 |
| Operating profit | 2.3 | 1.9 | 1.6 | 0.4 | 1.0 | 1.4 | 0.5 | 0.3 | 0.1 | 0.6 |
| Profit after tax | 1.2 | 0.9 | 0.8 | 0.3 | 0.8 | 1.3 | 0.4 | 0.2 | (0.0) | 0.4 |
| Profit attributable to shareholders | 1.0 | 0.8 | 0.7 | 0.3 | 0.7 | 1.2 | 0.4 | 0.2 | 0.0 | 0.4 |
| EPS – basic (Rs) Rs | 22.51 | 17.86 | 15.72 | 6.24 | 16.90 | 27.00 | 9.59 | 4.62 | 0.16 | 9.10 |
| Dividend per share (Rs) Rs | 5.50 | 4.00 | 3.00 | 0.00 | 4.17 | 8.33 | 2.78 | 4.17 | 1.39 | 4.86 |
| Total assets | 25.9 | 24.6 | 21.7 | 16.6 | 14.0 | 12.0 | 9.0 | 7.1 | 7.0 | 6.8 |
| Total equity | 15.6 | 14.5 | 11.8 | 8.4 | 8.3 | 7.9 | 6.6 | 5.6 | 5.6 | 5.7 |
| Total debt | 4.3 | 4.3 | 4.9 | 3.6 | 2.2 | 1.2 | 0.2 | 0.0 | 0.1 | 0.0 |
| Net cash from operating activities | 0.0 | 0.9 | (1.1) | (0.4) | 0.5 | 1.8 | 0.1 | 0.4 | 0.5 | 0.8 |
| Capital expenditure | (1.2) | (0.7) | (0.6) | (2.3) | (1.8) | (1.2) | (0.4) | (0.4) | (0.4) | (0.4) |
| Free cash flow (operating cash flow − capex) | (1.2) | 0.2 | (1.7) | (2.8) | (1.3) | 0.6 | (0.3) | 0.0 | 0.2 | 0.4 |
| Rs bn | TTM to Jun 2026 | Q4 FY2026 Apr – Jun 2026 | Q3 FY2026 Jan – Mar 2026 | Q2 FY2026 Oct – Dec 2025 | Q1 FY2026 Jul – Sep 2025 | Q4 FY2025 Apr – Jun 2025 | Q3 FY2025 Jan – Mar 2025 | Q2 FY2025 Oct – Dec 2024 | Q1 FY2025 Jul – Sep 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 24.0 | 5.8 | 5.6 | 6.7 | 5.9 | 4.5 | 5.1 | 4.7 | 4.5 |
| Gross profit | 10.7 | 2.5 | 2.5 | 3.1 | 2.6 | 2.0 | 2.1 | 2.1 | 1.9 |
| Operating profit | 2.5 | 0.6 | 0.5 | 0.7 | 0.6 | 0.6 | 0.5 | 0.5 | 0.6 |
| Profit after tax | 1.2 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.2 | 0.2 | 0.2 |
| Profit attributable to shareholders | 1.0 | 0.2 | 0.2 | 0.3 | 0.3 | 0.2 | 0.2 | 0.2 | 0.2 |
| EPS – basic (Rs) Rs | 22.51 | 5.59 | 4.78 | 6.19 | 5.95 | 4.74 | 4.59 | 3.46 | 5.07 |
| Dividend per share (Rs) Rs | 5.50 | 5.50 | 0.00 | 0.00 | 0.00 | 4.00 | 0.00 | 0.00 | 0.00 |
| Total assets | 25.9 | 25.9 | 26.5 | 26.8 | 24.5 | 24.6 | 24.4 | 27.4 | 24.1 |
| Total equity | 15.6 | 15.6 | 15.2 | 15.0 | 14.8 | 14.5 | 14.2 | 14.0 | 12.1 |
| Total debt | 4.3 | 4.3 | 4.9 | 4.1 | 3.7 | 4.3 | 4.3 | 7.0 | 5.0 |
| Net cash from operating activities | 0.0 | 0.2 | (1.3) | 0.4 | 0.8 | 0.5 | (0.2) | 0.7 | (0.0) |
| Capital expenditure | (1.2) | (0.3) | (0.6) | (0.2) | (0.1) | (0.2) | (0.1) | (0.3) | (0.1) |
| Free cash flow (operating cash flow − capex) | (1.2) | (0.1) | (1.9) | 0.2 | 0.6 | 0.3 | (0.3) | 0.4 | (0.2) |
Figures in Pakistani rupees as reported by the company; costs and cash outflows in brackets. Free cash flow and book value per share are calculated by Smart Money; TTM = the latest four quarters. Updated 17 Oct 2026.
FEROZ charts
Valuation
FEROZ valuation at today's price
- Price to earnings (P/E)
- 16.1×
- EPS Rs 22.51 (FY2026)
- Price to book (P/B)
- 1.19×
- Book value Rs 304.56 (FY2026)
- Dividend yield
- 1.5%
- DPS Rs 5.50 (FY2026)
- Earnings yield
- 6.2%
- EPS ÷ price
At the closing price of Rs 362.49 on 13 Nov 2026. P/E and P/B are not shown when earnings or book value are negative.
Sector peers
FEROZ vs Pharmaceuticals companies
| Company | Market cap | P/E | P/B | Yield | ROE | 3-yr growth |
|---|---|---|---|---|---|---|
| FEROZ | Rs 15.8 bn | 16.1× | 1.19× | 1.5% | 7.6% | 27.9% |
| GLAXO | Rs 107.1 bn | 10.3× | 3.11× | 5.1% | 32.4% | 16.3% |
| ABOT | Rs 97.9 bn | 11.4× | 3.05× | 4.0% | 28.8% | 15.2% |
| HALEON | Rs 81.6 bn | 12.4× | 5.02× | 4.3% | 47.6% | 16.2% |
| HINOON | Rs 50.8 bn | 12.8× | 3.95× | 5.2% | 32.3% | 20.5% |
| AGP | Rs 43.8 bn | 11.7× | 2.92× | 5.1% | 25.9% | 26.0% |
| HPL | Rs 38.5 bn | 10.3× | 4.50× | 6.0% | 38.6% | 18.6% |
| CPHL | Rs 14.5 bn | 18.3× | 1.34× | 0.0% | 7.3% | 4.3% |
| MACTER | Rs 12.0 bn | 17.7× | 2.87× | 0.0% | 17.4% | 20.7% |
Analyses & signals 0
Win rate — · 0 closed signals · average return —
No analyses published for FEROZ yet.
FEROZ: frequently asked questions
What is FEROZ's EPS?
Ferozsons Laboratories Limited reported basic earnings per share of Rs 22.51 for FY2026 (Jul 2025 – Jun 2026).
What is FEROZ's P/E ratio?
At the closing price of Rs 362.49 on 13 Nov 2026, FEROZ trades at a P/E of 16.1× based on EPS of Rs 22.51 (FY2026).
Does FEROZ pay dividends?
Yes. Ferozsons Laboratories Limited declared a dividend of Rs 5.50 per share for FY2026. It has paid a dividend in each of the last 3 years. At Rs 362.49 that is a dividend yield of 1.5%.
What was FEROZ's revenue and profit in FY2026?
Ferozsons Laboratories Limited reported revenue of Rs 24.0 bn and profit attributable to shareholders of Rs 978.6 mn for FY2026 (Jul 2025 – Jun 2026).
What is FEROZ's book value per share?
Ferozsons Laboratories Limited's book value per share was Rs 304.56 at the end of FY2026. The shares trade at 1.19× book value.
How has FEROZ's share price performed?
FEROZ's share price is down 3.5% year to date (KSE-100: +2.2%), down 8.7% over one year (KSE-100: +10.7%) and up 15.8% over five years (KSE-100: +288.8%), as of 13 Nov 2026. These are price returns; dividends are not included.
Information only, not investment advice.